Hyperhomocysteinemia : An Effect Reversible With Vitamin C Therapy Demonstration of Rapid Onset Vascular Endothelial Dysfunction After

Hyperhomocysteinemia : An Effect Reversible With Vitamin C Therapy Demonstration of Rapid Onset Vascular Endothelial Dysfunction After Print ISSN: 0009-7322. Online ISSN: 1524-4539 Copyright © 1999 American Heart Association, Inc. All rights reserved. is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231 Circulation doi: 10.1161/01.CIR.99.9.1156 1999;99:1156-1160 Circulation. http://circ.ahajournals.org/content/99/9/1156 World Wide Web at: The online version of this article, along with updated information and services, is located on the

[1]  S. Vollset,et al.  Plasma homocysteine levels and mortality in patients with coronary artery disease. , 1997, The New England journal of medicine.

[2]  J. Loscalzo,et al.  Homocyst(e)ine Decreases Bioavailable Nitric Oxide by a Mechanism Involving Glutathione Peroxidase* , 1997, The Journal of Biological Chemistry.

[3]  J. Deanfield,et al.  Non-invasive measurement of endothelial function: effect on brachial artery dilatation of graded endothelial dependent and independent stimuli. , 1997, Heart.

[4]  M. Creager,et al.  Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. , 1997, Circulation.

[5]  J. Loscalzo.  The oxidant stress of hyperhomocyst(e)inemia. , 1996, The Journal of clinical investigation.

[6]  C. Sobey,et al.  Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. , 1996, The Journal of clinical investigation.

[7]  D. Matthias,et al.  Homocysteine induced arteriosclerosis-like alterations of the aorta in normotensive and hypertensive rats following application of high doses of methionine. , 1996, Atherosclerosis.

[8]  P. Reitsma,et al.  Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. , 1996, The New England journal of medicine.

[9]  G. Omenn,et al.  A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. , 1995, JAMA.

[10]  W E Haefeli,et al.  Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. , 1995, Circulation.

[11]  A. Chait,et al.  Oxidation of low density lipoprotein by thiols: superoxide-dependent and -independent mechanisms. , 1993, Journal of lipid research.

[12]  D. Celermajer,et al.  Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. , 1993, Journal of the American College of Cardiology.

[13]  K. Shimada,et al.  Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. , 1993, The Journal of clinical investigation.

[14]  R. Clarke,et al.  Hyperhomocysteinemia: an independent risk factor for vascular disease. , 1991, The New England journal of medicine.

[15]  J. Ubbink,et al.  Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. , 1991, Journal of chromatography.

[16]  R. Ross,et al.  Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons. , 1983, Circulation research.

[17]  R. Ross,et al.  Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. , 1976, The Journal of clinical investigation.

[18]  K. Woo,et al.  Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. , 2000, Circulation.

[19]  J. Stamler,et al.  Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. , 1993, The Journal of clinical investigation.

[20]  R Busse,et al.  Crucial role of endothelium in the vasodilator response to increased flow in vivo. , 1986, Hypertension.